Indocyanine Green (ICG) in the ex Vivo Detection of Sentinel Lymph Node (SLN)in Colon Cancer (2068)
|ClinicalTrials.gov Identifier: NCT01995591|
Recruitment Status : Completed
First Posted : November 26, 2013
Last Update Posted : January 12, 2016
|Condition or disease|
|Colon Cancer Colon Surgery|
Primary objective Feasibility study of ex vivo injections of ICG to image and detect the sentinel lymph nodes in patients with colon cancer.
To determine the sensitivity of ICG in the dissected piece of colon cancer compared with the blue dye.
Evaluation of the influence of this approach on the up-staging of the patients
Microscopic study of the ICG distribution in the lymph nodes (in the lymphatic sinuses, in specific cells, in cancerous foci…)
In the operating room:
Patients will undergo standard surgical resection. Immediately after removal of the colon and node-bearing mesentery, using different 29 Gauge insulin syringes, blue dye (2 ml blue dye: 0.5 ml per injection) and ICG (2 ml with 0,5 mg ICG per ml: 0.5 ml per injection) will be injected in the fresh specimen beside each other submucosally around the tumour in at least four sites (as many injections needed to cover all the perimeter of the tumour) for each agent. The injection sites will be then gently stretched and massaged for 3-5 min to stimulate the tracers to flow along the lymphatic channels. Fluoroscopic imagings of the mesentery will be performed during the injections and during these manoeuvers.
The research and identification of the sentinel lymph nodes will be then performed as follows:
- he will first localize the blue colored lymph vessels (if visible) as well as the palpable and/or blue colored lymph nodes. These last ones will be marked for dissection with a blue suture.
- using the PDE camera, he will thereafter localize the fluorescent lymph vessels (if visible) as well as the palpable and/or fluorescent lymph nodes. These last ones will be marked for dissection with a green suture.
Histopathology in the Laboratory of Pathology:
When all SLN are identified, they will be dissected and classified as follows:
- SLN first seen as blue and confirmed also as fluorescent using PDE
- SLN seen as blue but not confirmed to be fluorescent using PDE
- SLN not directly visible as blue but seen fluorescent using PDE (the LN in this group will be controlled for their blue or not character when dissected)
- LN identified by the pathologist as pathological but not blue and not fluorescent.
After the dissection of these SLN, the specimen will be processed as usual using routine procedure for further examination of the non SLN by the pathologists. Once these lymph nodes are dissected, they will be tested for the emitted fluorescence.
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||Prospective Open-label Study Using ex Vivo Injection of ICG to Detect SLN in Patients With Colon Cancer|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||February 2013|
|Actual Study Completion Date :||February 2015|
- number of sentinel lymph nodes identified in pieces of colectomy from patients with colon cancer with Indocyanine Green [ Time Frame: 18 monthes ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01995591
|Jules Bordet Institute|
|Brussels, Belgium, 1000|
|Principal Investigator:||Gabriel Liberale, MD||Surgeon in Jules Bordet Institute|